arGEN-X Raises €40 million in successful Initial Public Offering on Euronext Brussels

Breda, the Netherlands / Ghent, Belgium – arGEN-X N.V. (arGEN-X), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, announces the successful completion of its Initial Public Offering, which was launched on 23 June 2014 (the IPO or the Offering). arGEN-X shares will be listed on Euronext Brussels and begin trading on an if-and-when-issued-or-delivered basis on Thursday 10 July 2014 under the symbol ARGX.